Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8888745 | ORGANON | Applicator for inserting an implant |
Aug, 2026
(3 years from now) | |
US10821277 | ORGANON | Kit for and method of assembling an applicator for inserting an implant |
May, 2027
(4 years from now) | |
US8722037 | ORGANON | X-ray visible drug delivery device |
Sep, 2027
(4 years from now) | |
US9757552 | ORGANON | Applicator for inserting an implant |
Jul, 2030
(7 years from now) |
Drugs and Companies using ETONOGESTREL ingredient
Market Authorisation Date: 17 July, 2006
Treatment: Prevention of pregnancy
Dosage: IMPLANT;IMPLANTATION
13
European Union
7
United States
4
South Africa
4
Australia
4
Norway
4
Argentina
4
Brazil
4
Korea, Republic of
4
China
4
Japan
4
Canada
4
New Zealand
3
Mexico
3
Hong Kong
3
Russia
3
Portugal
3
Spain
3
Peru
3
Taiwan, Province of China
3
Ukraine
2
Denmark
2
Slovenia
2
Poland
1
Israel
1
Austria
1
Egypt
1
Lithuania
1
Hungary
1
Latvia
1
Germany
1
Croatia
1
Cyprus
1
Malaysia
1
Ecuador
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8007830 | ORGANON | Granule formation |
Oct, 2022
(5 months ago) |
Drugs and Companies using MONTELUKAST SODIUM ingredient
Market Authorisation Date: 26 July, 2002
Treatment: NA
Dosage: GRANULE;ORAL
3
United States
2
Canada
1
South Africa
1
Denmark
1
Austria
1
Mexico
1
Australia
1
Egypt
1
Slovenia
1
Hungary
1
Norway
1
Germany
1
Croatia
1
Brazil
1
Portugal
1
Cyprus
1
Malaysia
1
Spain
1
Peru
1
Korea, Republic of
1
China
1
Ecuador
1
Japan
1
European Union
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7030106 | ORGANON | Sterol absorption inhibitor compositions |
Jan, 2022
(1 year, 2 months ago) | |
US7030106
(Pediatric) | ORGANON | Sterol absorption inhibitor compositions |
Jul, 2022
(8 months ago) | |
US7612058 | ORGANON | Methods for inhibiting sterol absorption |
Oct, 2025
(2 years from now) | |
US7612058
(Pediatric) | ORGANON | Methods for inhibiting sterol absorption |
Apr, 2026
(3 years from now) |
Drugs and Companies using EZETIMIBE ingredient
Market Authorisation Date: 25 October, 2002
Treatment: To reduce elevated total-c, ldl-c, apo b and non-hdl-c in patients with primary hyperlipidemia by administration of ezetimibe alone or in combination with a statin or with fenofibrate; Reduction of el...
Dosage: TABLET;ORAL
37
United States
17
European Union
12
Japan
9
Australia
9
Canada
8
Denmark
8
Austria
8
Hong Kong
8
Slovenia
8
Germany
8
Argentina
8
Portugal
8
Spain
8
China
7
Mexico
6
Hungary
6
Norway
6
Cyprus
6
Korea, Republic of
6
Ecuador
5
South Africa
5
Slovakia
5
Russia
5
Brazil
5
Czech Republic
5
New Zealand
4
Poland
4
Taiwan, Province of China
2
Israel
1
Turkey
1
Morocco
1
Yugoslavia
1
Malaysia
1
Peru
1
Chile
1
RS
1
Georgia
1
ME
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic